ANNOUNCER: In some cancers, such as several types of lymphoma, targeted therapy can increase the likelihood of a cure. In other cases, the newer drugs delay the progression of a fatal disease. As doctors and researchers continue to learn more about how cancer develops, they say more and better targeted drugs will become available. They payoff in improved treatment is likely to be significant.
PAUL BUNN, MD: So the promises of molecular targeted therapy and personalized medicine using specific therapies for a specific patient's tumor, are that we will cure many more patients with early stage disease and that patients that have advanced
disease that can't be cured will have a product life.
DAVID GARFIELD, MD: In all the years I've been in oncology, these past few years have been the most exciting. We were stuck with chemotherapy for years. The progress was slow and arduous. But now we're finding that these molecular targeted therapies work in a dramatic fashion, very quickly. For reasons that we understand, whereas we didn't understand the chemotherapy before, we're able to combine molecular targeted therapies and get a better response and so these are very, very fine times for us. The fruits of our labors over the last many decades are finally coming to fruition.
